Pulse Biosciences (NASDAQ:PLSE) Research Coverage Started at Mizuho

Mizuho assumed coverage on shares of Pulse Biosciences (NASDAQ:PLSE) in a report released on Friday, MarketBeat reports. The brokerage issued an outperform rating and a $25.00 price target on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $23.50.

Pulse Biosciences Stock Performance

PLSE stock opened at $13.83 on Friday. The firm has a market cap of $937.26 million, a price-to-earnings ratio of -12.24 and a beta of 1.77. The firm has a 50-day simple moving average of $14.10 and a two-hundred day simple moving average of $15.46. Pulse Biosciences has a one year low of $12.56 and a one year high of $25.00.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its holdings in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its stake in Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after purchasing an additional 1,372 shares during the last quarter. KLP Kapitalforvaltning AS increased its holdings in shares of Pulse Biosciences by 136.0% in the third quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after purchasing an additional 3,400 shares during the period. Finally, AlphaQuest LLC increased its holdings in shares of Pulse Biosciences by 184.5% in the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after purchasing an additional 5,748 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.